Published in
Taylor and Francis Group, Expert Review of Clinical Pharmacology, 1(15), p. 1-9, 2022
DOI: 10.1080/17512433.2022.2044791
Links
Tools
Dostarlimab for the treatment of advanced endometrial cancer
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 